These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 28830352

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Suppressor of cytokine signaling-1 mimetic peptides attenuate lymphocyte activation in the MRL/lpr mouse autoimmune model.
    Sharma J, Collins TD, Roach T, Mishra S, Lam BK, Mohamed ZS, Veal AE, Polk TB, Jones A, Cornaby C, Haider MI, Zeumer-Spataro L, Johnson HM, Morel LM, Larkin J.
    Sci Rep; 2021 Mar 18; 11(1):6354. PubMed ID: 33737712
    [Abstract] [Full Text] [Related]

  • 5. TNFAIP3 downregulation mediated by histone modification contributes to T-cell dysfunction in systemic lupus erythematosus.
    Zhao H, Wang L, Luo H, Li QZ, Zuo X.
    Rheumatology (Oxford); 2017 May 01; 56(5):835-843. PubMed ID: 28158872
    [Abstract] [Full Text] [Related]

  • 6. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus.
    Kawasaki M, Fujishiro M, Yamaguchi A, Nozawa K, Kaneko H, Takasaki Y, Takamori K, Ogawa H, Sekigawa I.
    Lupus; 2011 Oct 01; 20(12):1231-9. PubMed ID: 21980035
    [Abstract] [Full Text] [Related]

  • 7. Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor.
    Yan Q, Chen W, Song H, Long X, Zhang Z, Tang X, Chen H, Lin H, Sun L.
    Front Immunol; 2021 Oct 01; 12():675542. PubMed ID: 34394075
    [Abstract] [Full Text] [Related]

  • 8. EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.
    Wu L, Jiang X, Qi C, Zhang C, Qu B, Shen N.
    Front Immunol; 2021 Oct 01; 12():653989. PubMed ID: 33868295
    [Abstract] [Full Text] [Related]

  • 9. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
    Cai Z, Wong CK, Dong J, Chu M, Jiao D, Kam NW, Lam CW, Tam LS.
    Clin Exp Immunol; 2015 Aug 01; 181(2):253-66. PubMed ID: 25845911
    [Abstract] [Full Text] [Related]

  • 10. Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus.
    Satoh-Kanda Y, Nakayamada S, Kubo S, Yamagata K, Nawata A, Tanaka H, Kosaka S, Kanda R, Yu S, Fujita Y, Sonomoto K, Tanaka Y.
    RMD Open; 2024 Jun 13; 10(2):. PubMed ID: 38871479
    [Abstract] [Full Text] [Related]

  • 11. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
    Schmidt T, Paust HJ, Krebs CF, Turner JE, Kaffke A, Bennstein SB, Koyro T, Peters A, Velden J, Hünemörder S, Haag F, Steinmetz OM, Mittrücker HW, Stahl RA, Panzer U.
    Arthritis Rheumatol; 2015 Feb 13; 67(2):475-87. PubMed ID: 25385550
    [Abstract] [Full Text] [Related]

  • 12. In vivo anti-inflammatory activities of novel cytokine IL-38 in Murphy Roths Large (MRL)/lpr mice.
    Chu M, Tam LS, Zhu J, Jiao D, Liu H, Cai Z, Dong J, Kai Lam CW, Wong CK.
    Immunobiology; 2017 Mar 13; 222(3):483-493. PubMed ID: 27769564
    [Abstract] [Full Text] [Related]

  • 13. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
    Wang H, Li T, Chen S, Gu Y, Ye S.
    Arthritis Rheumatol; 2015 Dec 13; 67(12):3190-200. PubMed ID: 26245802
    [Abstract] [Full Text] [Related]

  • 14. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
    Sharabi A, Azulai H, Sthoeger ZM, Mozes E.
    Immunology; 2007 Jun 13; 121(2):248-57. PubMed ID: 17346282
    [Abstract] [Full Text] [Related]

  • 15. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
    Richter P, Cardoneanu A, Burlui AM, Macovei LA, Bratoiu I, Buliga-Finis ON, Rezus E.
    Int J Mol Sci; 2022 Oct 04; 23(19):. PubMed ID: 36233087
    [Abstract] [Full Text] [Related]

  • 16. The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
    Goropevšek A, Holcar M, Avčin T.
    Clin Rev Allergy Immunol; 2017 Apr 04; 52(2):164-181. PubMed ID: 27216430
    [Abstract] [Full Text] [Related]

  • 17. Ifi202, an IFN-inducible candidate gene for lupus susceptibility in NZB/W F1 mice, is a positive regulator for NF-kappaB activation in dendritic cells.
    Yamauchi M, Hashimoto M, Ichiyama K, Yoshida R, Hanada T, Muta T, Komune S, Kobayashi T, Yoshimura A.
    Int Immunol; 2007 Aug 04; 19(8):935-42. PubMed ID: 17702989
    [Abstract] [Full Text] [Related]

  • 18. Effects of 1,25(OH)2 D3 and vitamin D receptor on peripheral CD4+ /CD8+ double-positive T lymphocytes in a mouse model of systemic lupus erythematosus.
    Ding Y, Liao W, He XJ, Xiang W.
    J Cell Mol Med; 2017 May 04; 21(5):975-985. PubMed ID: 28063200
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
    Yang J, Li Q, Yang X, Li M.
    Mol Med; 2015 Apr 15; 21(1):364-70. PubMed ID: 25902303
    [Abstract] [Full Text] [Related]

  • 20. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
    Lee J, Park Y, Jang SG, Hong SM, Song YS, Kim MJ, Baek S, Park SH, Kwok SK.
    Front Immunol; 2021 Apr 15; 12():704526. PubMed ID: 34497607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.